Hemodialysis

Nephrology
2
Pipeline Programs
3
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

CP
Chugai PharmaJapan - Tokyo
1 program
1
Sevelamer HClPhase 41 trial
Active Trials
NCT01755078Completed166Est. Jun 2009
Regeneron
RegeneronTARRYTOWN, NY
1 program
1
Alirocumab 150 MG/ML [Praluent]Phase 31 trial
Active Trials
NCT03480568Unknown20Est. Dec 2020
Merit Medical
Merit MedicalSOUTH JORDAN, UT
1 program
HeRO Vascular Access DeviceN/A1 trial
Active Trials
NCT00889564Completed38Est. Mar 2007

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Chugai PharmaSevelamer HCl
RegeneronAlirocumab 150 MG/ML [Praluent]
Merit MedicalHeRO Vascular Access Device

Clinical Trials (3)

Total enrollment: 224 patients across 3 trials

Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients

Start: Jun 2007Est. completion: Jun 2009166 patients
Phase 4Completed
NCT03480568RegeneronAlirocumab 150 MG/ML [Praluent]

Alirocumab in Patients on a Stable Dialysis Regimen

Start: May 2018Est. completion: Dec 202020 patients
Phase 3Unknown
NCT00889564Merit MedicalHeRO Vascular Access Device

HeRO Vascular Access Device Bacteremia Study

Start: Mar 2006Est. completion: Mar 200738 patients
N/ACompleted

Related Jobs in Nephrology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space